A phase II study of S-1 in patients with metastatic pancreatic cancer
A phase II study of S-1 in patients with metastatic pancreatic cancer
复制标题
S-1 在转移性胰腺癌患者中的 II 期研究
DOI：
10.1200/jco.2005.23.16_suppl.4104
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
H. Saito
中科院分区：
文献类型：
--
作者：
J. Furuse;T. Okusaka;A. Funakoshi;N. Boku;K. Yamao;S. Ohkawa;H. Saito
4104 背景：本研究的目的是确定 S-1 对转移性胰腺癌患者的疗效和毒性。 S-1是一种口服抗癌剂，含有替加氟（FT：5-氟尿嘧啶的前药）、5-氯-2,4-二羟基吡啶（CDHP：脱氢嘧啶脱氢酶抑制剂）和氧酸钾（Oxo：乳清酸磷酸核糖基转移酶抑制剂），摩尔比为FT:CDHP:Oxo = 1:0.4:1。方法：经组织学或细胞学证实、二维可测量的转移性胰腺癌且不适合手术或放疗的患者符合本研究的资格。其他资格标准包括卡诺夫斯基表现状态为 80% 至 100%；年龄20至74岁；足够的血液、肾和肝功能；既往未接受化疗；和书面知情同意书。 S-1 口服给药 (40 mg/m2) b.i.d.连续 28 天，每 6 周重复一次。患者继续接受额外的 S-1 疗程，直到疾病进展或...
4104 Background: The purpose of this study was to determine the efficacy and toxicity of S-1 in patients with metastatic pancreatic cancer. S-1, an oral anticancer agent, contains tegafur (FT: a prodrug of 5-fluorouracil), 5-chloro-2,4-dihydroxypyridine (CDHP: a dehydropyrimidine dehydrogenase inhibitor), and potassium oxonate (Oxo: an orotate phosphoribosyl transferase inhibitor) at a molar ratio of FT:CDHP:Oxo = 1:0.4:1. Methods: Patients with histologically or cytologically confirmed, bidimensionally measurable metastatic pancreatic adenocarcinoma not amenable to surgery or radiotherapy were eligible for the study. Other eligibility criteria included a Karnofsky performance status of 80 to 100%; an age of 20 to 74 years; adequate hematological, renal and liver functions; no prior chemotherapy; and written informed consent. S-1 was administered orally (40 mg/m2) b.i.d. for 28 consecutive days, repeated every 6 weeks. Patients continued to receive additional courses of S-1 until disease progression or th...